Company intelligence / Profile preview

TOPPAN Holdings

Tokyo, Tokyo Prefecture, Japan

Ownership: Private
Employees: ~50000
Development stage: Other

Overview

TOPPAN Holdings has developed invivoid™, a proprietary 3D cell culture platform for artificial liver tissue and organoid systems, demonstrated to have improved translational potential compared to traditional models; recent partnerships (e.g., PhoenixBio, MD Anderson) aim to validate and broaden use for preclinical drug testing and personalized cancer medicine[1][9].

Therapeutic areas: OncologyOther
Modalities: 3D cell culture technologyArtificial organoid-based modelsPlatform technology for in vitro tissue engineering
Industry: Non-Drug Biotech

Partnerships

PhoenixBio (biotech, artificial liver tissue)MD Anderson Cancer Center (organoid technologies for cancer research)Myoridge (cell culture R&D)

Beyond the preview

Go deeper on TOPPAN Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOPPAN Holdings.

Explore the full profile